Experts raise questions about current standards of drug regulation

by British Medical Journal Credit: CC0 Public Domain
A growing number of drugs are being approved on the basis of indirect (‘surrogate’) measures that do not always reliably predict outcomes that matter most to patients, such as living longer or feeling better. In The BMJ today, experts argue that surrogate endpoints provide no guarantee of clinical benefit and should be used only as a last resort in drug trials .

Read the source article at Medical Xpress
2021-09-16 02:30:00